| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581897 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 7 Pages |
Abstract
Patients with relapsed or refractory DLBCL experiencing relapse > 1 year after ASCT had good outcomes. Despite the relative rarity in incidence, a significant risk of relapse of DLBCL after ASCT remains, suggesting the need for continued monitoring because of the possibility of later progression.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Bradley D. Hunter, Megan Herr, Philip J. Meacham, Ferdous Barlaskar, Andrew G. Evans, W. Richard Burack, Jane L. Liesveld, Michael W. Becker, Laurie A. Milner, Louis S. Constine, Sughosh Dhakal, Paul M. Barr, Jonathan W. Friedberg, Carla Casulo,